Big pharma companies are actively looking outwards for innovative new therapeutics to add to their pipelines. This panel brings together speakers from various big pharma companies discussing topics such as:

• How big pharma sources assets
• The evaluation process
• Key factors and areas of interest
• How early-stage big pharma is willing to look

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

This panel will feature investors that focus on longevity. Learn about their investment preferences and how they evaluate and manage their relationships with their early-stage portfolio and prospects in this specific market. Hear from active age-tech experts on their predictions for the future of this sector.

Healthcare organizations are embracing innovations and becoming a key training ground to test the medical benefits, technical feasibility, and business viability of new technology breakthroughs. From innovation centers to investment vehicles, healthcare organizations have become critical partners for entrepreneurs. This panel will reveal the changing role healthcare organizations are playing in fostering innovation. Topics may include:

• What are hospitals and health networks doing to engage with new technology companies?
• How can a startup get the most out of conducting pilot studies with a healthcare system partner?
• How do early stage companies work with healthcare systems to generate user experience for their new technologies?
• How can healthcare organizations share their technical expertise with startups?

This RESI panel will help entrepreneurs navigate complex healthcare systems and bring their companies to the next milestone.

This panel focuses on understanding how family offices view direct investments in early-stage healthcare opportunities (seed – series A) and how they differ from and compare to VCs. Topics may include:

• Primary differences between institutional VCs and family office investors
• How family offices source investments / how to get on their radar
• Trends in the early-stage healthcare investment space

The primary goal of this panel is to help entrepreneurs understand how family offices view early-stage investments in the healthcare space and best practices for approaching, pitching, and working with these groups as well as debunking some common misconceptions about family offices.

This panel focuses on the many applications of AI in healthcare, from pathology applications to diagnostics to personalized medicine.

Topics may include:

• What are investors looking for when evaluating companies in this space
• Where is AI in healthcare now and where is it going
• What are the current challenges facing AI, including regulatory challenges

In recent years, numerous technologies integrating AI have come up in the life sciences & healthcare industry. From drug discovery platforms to remote patient monitoring, AI plays a big role in a lot of the up and coming startups in this space. In this panel, we hope to uncover areas that pique investors’ interests at this current time. In addition, panelists can discuss the associated risks, such as regulatory or ethical complexities, data quality, among others.

Venture capital gets a lot of attention, but it is not the only source of funding. This panel explores a diverse range of alternative funding sources for early-stage companies such as angel investors, family offices, grants, and more. Hear about the overlooked channels of capital and learn what these funders are looking for and how to access them.

Topics may incldue:

• How does your approach to funding differ from traditional sources like banks or venture capital?
• What factors do you consider when evaluating funding opportunities?
• How do you see the landscape of alternative funding evolving in the next few years?
• What advice would you give to those seeking funding from organizations like yours?

This panel will open up new possibilities for an entrepreneur’s funding journey. Because early-stage capital is not one-size-fits-all, thinking beyond traditional venture capital could be the key to unlocking a startup’s next big move.

CNS Diseases can affect anyone, from children suffering from genetic disorders to elderly suffering from neurological diseases such as dementia in all its forms, as well as mental and behavioral disorders, that can appear at any age. Investing in technologies relating to CNS disorders remains high, among the most well-funded indications. Panel topics may include:

• What areas of CNS are saturated and what areas need more attention?
• What are common red flags seen when investing?
• What makes a company stand out in CNS?

As much as treating CNS diseases has been in the forefront for decades, investors are still seeking innovation, whether new and more complex therapeutics that can cross the blood-brain barrier, new treatments and preventions for neurodegenerative diseases, better diagnostic tests and treatments for mental and behavioral health, or devices that can restore function, among others. The more researchers learn, the greater the mystery of the central nervous system; panelists will discuss what are the newest and most exciting innovations in the CNS landscape.

The medical device industry continues to experience rapid growth, driven by technological innovation, regulatory advancements, and increasing global healthcare demand. This panel brings together active investors to discuss the latest trends, opportunities, and challenges in the medical device industry.

Topics addressed may include:

• Emerging technologies and current trends that excite investors
• Investment strategies and due diligence process on medical device opportunities
• Navigating regulatory hurdles and barriers to market entry
• Case studies of successful medical device investments

This panel will be an insightful discussion on how investors capitalize on this dynamic sector while driving advancements in patient care and medical technology.